The cognitive, subjective, and physical effects of a Ginkgo biloba/Panax ginseng combination in healthy volunteers with neurasthenic complaints

Psychopharmacology Bulletin

Volumn 33, Issue 4, 1997, Pages 677-683

  Wesnes, Keith A ^a   Faleni, R A ^b   Hefting, N R ^c   Hoogsteen, G ^d   Houben, J J G ^d   Jenkins, E ^a   Jonkman, J H G ^c   Leonard, J ^d   Petrini, O ^b   Van Lier, J J ^c  

^a Cognitive Drug Research Ltd ^*  (United Kingdom)

^b Pharmaton SA   (Switzerland)

^c PRA International USA   (Netherlands)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Computerized cognitive function tests; Dose response; Exercise capacity; Ginkgo biloba; Panax ginseng; Pharmacodynamics

Indexed keywords

GINKGO BILOBA EXTRACT; PLACEBO;

ADULT; AGED; BICYCLE ERGOMETRY; CLINICAL TRIAL; COGNITION; COMPUTER SYSTEM; CONFERENCE PAPER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; GINSENG; HUMAN; MAJOR CLINICAL STUDY; MALE; NEURASTHENIA; PERFORMANCE; PRIORITY JOURNAL; QUESTIONNAIRE;

ADULT; AGED; COGNITION; EMOTIONS; FEMALE; HUMANS; MALE; MEMORY; MIDDLE AGED; NEURASTHENIA; PANAX; PLANT EXTRACTS; PLANTS, MEDICINAL;

EID: 0031404977     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Baranov, AI. Medical uses of ginseng and related plants in the Soviet Union: Recent trends in the Soviet literature. J. Ethnopharmacol. 6:339-353, 1986.
2. Berman, I; Pappas, D; Leventhal, N; Osser, D; Sigadel, R; and Patel, C. Ginkgo biloba extract in schizophrenic patients. Poster presented at the 37th Annual NCDEU Meeting, Boca Raton, Florida, May 27-30, 1997.
3. Bond, A, and Lader, M. The use of analogue scales in rating subjective feelings. Br. J. Med. Psychol. 80:1-46, 1974.
4. Frey, PW, and Colliver, JA. Sensitivity and response measures for discrimination learning. Learn. Motiv. 4:327-342, 1973.
5. Hoffmann, NG, and Overall, PB. Factor structure of the SCL-90 in a psychiatric population. J. Consult. Clin. Psychol. 46:1187-1191, 1978.
6. Hopfenmüller, W. Nachweis der therapeutischen Wirksamkeit eines Ginkgo biloba Spezialextraktes. Arzneimittelforschung/Drug Research 44:1005-1013, 1994.
7. Kass, F; Charles, E; Klein, DF; and Cohen, P. Discordance between the SCL-90 and therapists psychopathology ratings. Arch. Gen. Psychiatry 40:369-393, 1983.
8. Kleijnen, J, and Knipschild, P. Ginkgo biloba for cerebral insufficiency. Br. J. Clin. Pharmacol. 34:352-358, 1992a.
9. Kleijnen, J, and Knipschild, P. Ginkgo biloba for cerebral insufficiency. The Lancet 340:1136-1139, 1992b.
10. Petkov, VD; Belcheva, S; Konstantinova, E; Kehayov, R; Petkov, VV; and Hadjiivanova, Chr. Participation of the serotonergic system in the memory effects of Ginkgo biloba L. and Panax ginseng C.A. Meyer. Phytother. Res. 8(8):470-477, 1994.
11. Petkov, VD; Kehayov, R; Belcheva, S; Konstantinova, E; Petkov, VV; Getova, D; and Markouska, V. Memory effects of standardized extracts of Panax ginseng (G115), Ginkgo biloba (GK501) and their combination in Gincosan® (PHL-00701). Planta Med. 59 (No. 2):106-114, 1993.
12. Rai, GS; Shovlin, C; and Wesnes, K. A double-blind, placebo controlled study of Ginkgo biloba extract ('Tanakan') in elderly outpatients with mild to moderate memory impairment. Curr. Med. Res. Opin. 12:350-355, 1991.
13. SAS Institute Inc. SAS Users Guide. 5th ed. Cary, NC: SAS Institute Inc., 1985.
14. Schilcher, H. Ginkgo biloba L. Untersuchungen zur Qualität, Wirkung, Wirksamkeit und Unbedenklichkeit. Zeitschift für Phytotherapie 9:119-127, 1988.
15. van Harten, J; Olff, M; Wesnes, K; and Strobel, W. Flesinoxan improves cognition in the elderly. Eur. Neuropsychopharmacol. 6(Suppl. 3):186, 1996.
16. Wesnes, K; Jones, RW; and Kirby, J. The effects of D-cycloserine, a glycine agonist, in a human model of the cognitive deficits associated with ageing and dementia. Br. J. Clin. Pharmacol. 31:577P-578P, 1991.
17. Wesnes, K; Neuman, E; de Wilde, HJG; Malbezin, M; Castagne, I; Crijns, HJMJ; Jonkman, JHG; and Guez, D. Pharmacodynamic effects of a repeated oral administration of 4 dose levels of S12024-2 in 32 elderly volunteers. Neurobiol. Ageing 15:100, 1994.
18. Wesnes, K; Simmons, D; Rook, M; and Simpson, PM. A double blind placebo controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly. Hum. Psychopharmacol. 2:159-171, 1987a.
19. Wesnes, K, and Simpson, PM. The effects of scopolamine in young subjects: A psychopharmacological model of ageing? Pharmacopsychiatry 21:68, 1988.
20. Wesnes, K; Simpson, PM; and Christmas, L. The assessment of human information processing abilities in psychopharmacology. In: Hindmarch, I, and Stonier, PD, eds. Human Psychopharmacology: Measures and Methods, Volume 1. Chichester: Wiley and Sons, 1987b. pp. 79-92.
21. Wesnes, K; Simpson, PM; Christmas, L; Anand, R; and McClelland, GR. The cognitive effects moclobemide and trazodone alone and in combination with ethanol in healthy elderly subjects. Br. J. Clin. Pharmacol. 27:647P-648P, 1989a.
22. Wesnes, K; Simpson, PM; Christmas, L; Anand, R; and McClelland, GR. The effects of moclobemide on cognition. J. Neurol. Transm. 29:91-102, 1989b.
23. Wesnes, K; Simpson, PM; and Kidd, AG. An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg. Hum. Psychopharmacol. 3:27-43, 1988.
24. Wesnes, K; Simpson, PM; and Kidd, AG. The use of a scopolamine model to study the nootropic effects of tenilsetam (CAS 997) in man. Med. Sci. Res. 15:1063-1064, 1987c.
25. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Diagnostic Criteria for Research. Geneva, Switzerland: World Health Organization, 1993.